Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (also referenced as Quoin Pharmaceuticals, Ltd. in metadata) for the month of June 2017, specifically dated June 9, 2017. The registrant is a foreign private issuer based in Kfar Saba, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a vehicle to distribute a press release rather than a financial report.
Material Changes
The primary material event disclosed is a change in the company's trading venue. Cellect Biotechnology Ltd. announced it is moving to trade exclusively on the NASDAQ stock market.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release dated June 9, 2017, titled "Cellect is moving to trade exclusively on the NASDAQ." The document does not contain specific financial guidance, management commentary on operational outlook, or a discussion of risks and contingencies beyond the trading venue change.
Investor Verification Checklist
- Verify the effective date of the exclusive NASDAQ listing.
- Confirm the ticker symbol and trading details on NASDAQ.
- Review the full text of the attached press release (Exhibit 99.1) for additional context on the transition.
- Check subsequent filings for any financial updates related to this corporate action.